Literature DB >> 26185038

GII.4 Sydney_2012 norovirus infection in immunocompromised patients in Beijing and its rapid evolution in vivo.

Huan Mai1, Yan Gao1, Xu Cong2, Hui Wang3, Ning Liu3, Xiaojun Huang4, Lanping Xu4, Yuhong Chen4, Lai Wei2.   

Abstract

To study the epidemiology and evolution of norovirus (NoV) in immunocompromised patients in a tertiary hospital in China. Stool specimens were collected from 131 hospitalized patients presenting with diarrhea from July 1, 2012, to June 30, 2013, and were tested for NoV using RT-PCR. RT-PCR was performed to amplify the complete capsid genome for a series of samples from chronic diarrhea patients, and nucleotide and amino acid changes were analyzed. There were nine NoV-positive patients among 124 immunocompromised patients (7.3%); all nine were infected with GII.4 Sydney_2012 strain. In three chronic diarrhea patients, the GII.4 Sydney_2012 strains accumulated 19, 18, and eight nucleotide mutations within 110, 113, and 22 days, respectively, most were non-synonymous. The greatest number of stable amino acid mutations was 10 in patient 2; eight stable mutations (including three in antigenic sites) occurred while the patient was asymptomatic and shedding the virus. GII.4 Sydney_2012 strain tends to undergo stable mutations during the asymptomatic shedding phase and may generate new variants in chronic diarrhea patients.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  GII.4 Sydney_2012; diarrhea; evolution; immunocompromised host; norovirus

Mesh:

Substances:

Year:  2015        PMID: 26185038     DOI: 10.1002/jmv.24332

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  6 in total

1.  Epidemiology of Norovirus Infection Among Immunocompromised Patients at a Tertiary Care Research Hospital, 2010-2013.

Authors:  Karin Bok; D Rebecca Prevots; Alison M Binder; Gabriel I Parra; Sara Strollo; Gary A Fahle; Allison Behrle-Yardley; Jordan A Johnson; Eric A Levenson; Stanislav V Sosnovtsev; Steven M Holland; Tara N Palmore; Kim Y Green
Journal:  Open Forum Infect Dis       Date:  2016-09-08       Impact factor: 3.835

Review 2.  Epidemiology and evolution of Norovirus in China.

Authors:  Na Wei; Jun Ge; Changyao Tan; Yunlong Song; Shiwei Wang; Mengru Bao; Jianqiang Li
Journal:  Hum Vaccin Immunother       Date:  2021-09-08       Impact factor: 4.526

3.  Increased and prolonged human norovirus infection in RAG2/IL2RG deficient gnotobiotic pigs with severe combined immunodeficiency.

Authors:  Shaohua Lei; Junghyun Ryu; Ke Wen; Erica Twitchell; Tammy Bui; Ashwin Ramesh; Mariah Weiss; Guohua Li; Helen Samuel; Sherrie Clark-Deener; Xi Jiang; Kiho Lee; Lijuan Yuan
Journal:  Sci Rep       Date:  2016-04-27       Impact factor: 4.379

4.  A next generation sequencing-based method to study the intra-host genetic diversity of norovirus in patients with acute and chronic infection.

Authors:  Maria E Hasing; Bart Hazes; Bonita E Lee; Jutta K Preiksaitis; Xiaoli L Pang
Journal:  BMC Genomics       Date:  2016-07-01       Impact factor: 3.969

5.  Intra-Host Evolution of Norovirus GII.4 in a Chronic Infected Patient With Hematopoietic Stem Cell Transplantation.

Authors:  Jie-Mei Yu; Ze-Yin Liang; Ke Guo; Xiao-Man Sun; Qing Zhang; Yu-Jun Dong; Zhao-Jun Duan
Journal:  Front Microbiol       Date:  2020-03-09       Impact factor: 5.640

6.  Human Norovirus Epitope D Plasticity Allows Escape from Antibody Immunity without Loss of Capacity for Binding Cellular Ligands.

Authors:  Lisa C Lindesmith; Paul D Brewer-Jensen; Michael L Mallory; Boyd Yount; Matthew H Collins; Kari Debbink; Rachel L Graham; Ralph S Baric
Journal:  J Virol       Date:  2019-01-04       Impact factor: 5.103

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.